Biologics market to generate $248.2bn in 2020, new visiongain analysis predicts

04 September 2018
Pharma

A report published in July 2016 by visiongain predicts that the worldwide biological drugs market will be worth $248.2 billion in 2020. That revenue forecast and others appear in Biologics Market Trends and Forecasts 2016-2026: Evaluation of Therapeutic Segments Including Monoclonal Antibodies, Insulin, Fusion Proteins, Interferons and Gene Therapies; Prediction of Leading National Markets (US, Japan, EU5 and BRIC); Investigation of Top Products Including Humira, Remicade, Lantus and Enbrel; and Assessment of R&D Including Sirukumab and NurOwn.

Visiongain is a business information publisher and consultancy in London, UK. Its purpose is to help companies and other organisations assess the potentials of industries and markets.

Arshad Ahad, a senior pharmaceutical industry analyst in visiongain, said: “Biologics are crucial for the treatment of many serious chronic disorders such as cancer, diabetes, hepatitis and autoimmune diseases. These effective but highly complex therapies come at a price, with some treatments costing more than $75,000 a year. They are able to generate multi-billion dollar revenues, with biologics representing eight out of the top ten best-selling drugs in 2015.

“The emergence of biosimilars is set to disrupt this market - although they can be a positive or a negative influence, depending on how companies adapt to their presence. Patents on many leading biologics are due to expire during the forecast period of our report, and payers are eager to cut costs in the face of declining healthcare budgets. As such, this is a crucial period in the history of the global biologics market, one which will determine its long term future.”

Along with revenue prediction for the overall world market for biologics, Visiongain’s new investigation shows forecasts from 2016 to 2026 for 13 individual submarkets:

• Protein therapeutics, with sub-forecasting for insulin, other recombinant hormones, plasma and recombinant coagulating factors, interferons, enzyme replacement and other agents
• Monoclonal antibodies (mAbs)
• Fusion proteins
• Regenerative medicine, with sub-forecasting for stem cell treatment, tissue engineering and gene therapy
• Vaccines.

In addition that work shows revenue forecasts for 18 leading products, including Lantus, Humalog, Avonex, Rebif, Humira, Remicade, Herceptin and Enbrel.

The analyses also show overall biologic revenue forecasts to 2026 for 11 national markets:

• United States
• Japan
• Germany, France, United Kingdom, Italy and Spain (EU5)
• Brazil, Russia, India and China (BRIC).

That updated study examines the worldwide biological drugs industry and market, exploring news, data, progress, trends, companies, products, R&D and biosimilars. Companies the work studies include Amgen, Bayer, Eli Lilly, GSK, Johnson & Johnson, Merck & Co., Novartis, Novo Nordisk, Pfizer, Roche and Sanofi.

Biologics Market Trends and Forecasts 2016-2026 adds to visiongain’s reports on industries and markets in healthcare. That portfolio contains studies on pharmaceuticals, biotechnology, diagnostics and medical devices.

Recent News

“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.

21 June 2019

Read

“Top 25 Vaccines market set to grow to $41bn by 2024” says new Visiongain report

There is an increasing focus to identify diseases that currently do not have a vaccine.

20 June 2019

Read

“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

The market for ophthalmic drugs is a growing one.

17 June 2019

Read

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever